Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
Poloxamer 188 For Injection BP EP USP Pharma Grade has shaped modern pharmaceutical science with its ability to serve as a non-ionic surfactant and emulsifier. It comes from a family of block copolymers, developed to solve everyday challenges in medicine formulation, drug delivery, and patient safety. Within the clinical setting, its significance comes from its use as an excipient, providing stability, solubility, and comfort in injections.
This material turns up in a range of physical forms reflecting the needs of both hospital and industrial contexts. Manufacturers supply Poloxamer 188 as solid flakes, pure white crystalline powder, discrete pearls, or highly viscous liquids. Each form answers different logistics — solid flakes simplify bulk transport and long shelf life, while a liquid solution can be drawn directly for formulations. Poloxamer 188 melts between 52°C and 57°C, making it easy to liquefy without harsh treatments. When dissolved, it creates a clear solution, showing the absence of contaminants.
Chemically, Poloxamer 188 presents as a triblock copolymer made of ethylene oxide and propylene oxide units, arranged as poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide). Its empirical molecular formula often appears as C64H128O32, and it carries a mean molecular weight of about 8400 g/mol. The unique structure, with two ends that love water and a center that resists it, brings versatility to its interactions — both with living tissue and other chemicals inside pharmaceutical solutions.
Strict monographs in BP (British Pharmacopoeia), EP (European Pharmacopoeia), and USP (United States Pharmacopeia) outline what pharmaceutical companies expect in this ingredient. Any batch intended for injection has to meet benchmarks for appearance, identity, solubility, pH (typically between 5.0–7.4 in a 5% aqueous solution), and purity. Tests screen for residual solvents, peroxide content, and microbial contamination, setting a high bar for safety. The density of Poloxamer 188 solid hovers between 1.05 and 1.10 g/cm³. A 10% w/v solution usually maintains a viscosity suitable for injectable products, balancing flow and stability.
Manufacturers and exporters categorize Poloxamer 188 using the Harmonized System Code 3402.13, placing it under organic surface-active agents—non-ionic types. This classification streamlines global trade, aiding supply chain partners in documentation, shipment, and customs clearance. Pharmacological grades carry certification under BP, EP, or USP, assuring end-users that the raw material fits pharmaceutical standards and demands for patient safety.
In mixtures, Poloxamer 188 shows low toxicity, with LD50 values in animal testing far higher than levels seen clinically. It acts as a mild non-ionic surfactant, lowering surface tension without forming harsh interactions or toxic byproducts. This ingredient does not hydrolyze easily, and it stands up against common oxidizers during routine storage. Its solubility in water and many alcohols, combined with thermal stability, means it resists the kinds of degradation that might otherwise limit shelf life.
Poloxamer 188 for injection displays as a white, free-flowing solid, either in powder or pearled form, with no visible odor. Under microscope, its crystal structure typically reflects well-ordered arrangement. Density ranges as mentioned previously, and the material dissolves readily, forming a transparent, low-viscosity solution even at room temperature. During handling, standard PPE suits the risks — contact with eyes can cause transient irritation; gloves and goggles avoid these annoyances. Poloxamer 188 rarely generates dust under normal conditions, although working in well-ventilated spaces remains standard.
Toxicologists long ago noted Poloxamer 188’s gentle interaction with human tissues. Eye and skin irritation rates fall low, reactions tend to be rare, and systemic toxicity stays well within safe margins at pharmaceutical doses. With that said, large-scale storage brings typical chemical safety routines. As with all injectable excipients, contamination or mislabeling can pose significant hazards, not because of the material itself, but due to possible process failures. Poloxamer 188 does not support combustion, and does not accrue significant health risks under REACH or GHS hazardous chemical classifications when properly handled as a pharmaceutical raw material.
Production starts with high-purity ethylene oxide and propylene oxide, with synthesis tightly regulated to avoid contamination with toxic by-products. Suppliers run each lot through quality testing, using chromatography and spectroscopy to check chain lengths, block ratios, and absence of low-molecular impurities. For injectable grade, each batch undergoes additional bacterial endotoxin and sterility tests, since even trace contamination could jeopardize patient safety. Reliable Poloxamer 188 delivers predictable results, helping formulators design medicines that dissolve smoothly, pass regulatory inspection, and provide comfort to the patient.
Medicines need excipients that dissolve briskly, deliver active ingredients without fuss, and avoid harming patients. In my own time working with injection formulations, Poloxamer 188 stands out for avoiding blood hemolysis, reducing injection site pain, and acting as an adaptable stabilizer. Regulatory agencies cast a strict light on every batch, ensuring that what goes into a medicine supports its mission to save lives, not endanger them. Given its reliable properties, molecule structure, and documented performance, Poloxamer 188 for injection keeps earning trust across pharmaceutical, biotech, and even veterinary use. Raw material quality links every step of the medicine pipeline—from chemical sourcing to patient care—making responsible sourcing and testing more than a paperwork exercise. It’s part of what makes modern therapy both possible and safe.
Chengguan District, Lanzhou, Gansu, China
